Calcifediol
For Laboratory Research Only. Not for Clinical or Personal Use.
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Calcifediol
Description :
Calcifediol (25-hydroxy Vitamin D3) is an effective VDR ligand and VD supplement. Calcifediol is a prohormone of the vitamin D endocrine system (VDES) and is hydroxylated in the liver to produce the active form, calcitriol. Calcifediol can rapidly increase serum VD levels[1][2][3].Product Name Alternative :
25-Hydroxy Vitamin D3UNSPSC :
12352211Hazard Statement :
H301Target :
Endogenous Metabolite; VD/VDRType :
Natural ProductsRelated Pathways :
Metabolic Enzyme/Protease; Vitamin D Related/Nuclear ReceptorApplications :
Metabolism-sugar/lipid metabolismField of Research :
Metabolic DiseaseAssay Protocol :
https://www.medchemexpress.com/Calcifediol.htmlPurity :
99.94Solubility :
DMSO : ≥ 100 mg/mLSmiles :
C=C(CC1)/C(C[C@H]1O)=C\C=C2[C@@]3([H])[C@@](CCC\2)(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC3Molecular Formula :
C27H44O2Molecular Weight :
400.64Precautions :
H301References & Citations :
[1]Castoldi A, et al. Calcifediol-loaded liposomes for local treatment of pulmonary bacterial infections. Eur J Pharm Biopharm. 2016 Nov 22.|[2]Wei Zheng, et al. Vitamin D-induced vitamin D receptor expression induces tamoxifen sensitivity in MCF-7 stem cells via suppression of Wnt/β-catenin signaling. Biosci Rep. 2018 Dec 7;38 (6) :BSR20180595.Shipping Conditions :
Blue IceStorage Conditions :
-20°C, 3 years (Powder)Scientific Category :
Natural ProductsClinical Information :
LaunchedIsoform :
Human Endogenous MetaboliteCitation 01 :
Front Pharmacol. 2020 Mar 31;11:200.|Int Immunopharmacol. 2023 Sep:122:110558.|Int J Mol Sci. 2017 Dec 19;18 (12) . pii: E2764.|Int J Mol Sci. 2025 Mar 25;26 (7) :2985.|J Sep Sci. 2025 Apr;48 (4) :e70130.|Nat Chem Biol. 2022 Nov;18 (11) :1196-1203.|Proc Natl Acad Sci U S A. 2022 Apr 12;119 (15) :e2117004119.|Ther Adv Endocrinol Metab. 2020 Oct 20:11:2042018820958295.|Virol Sin. 2024 Aug 19:S1995-820X (24) 00134-2.|Sci Rep. 2022 Feb 22;12 (1) :3014.CAS Number :
[19356-17-3]

